TPG Eyes $5B Exit From Healthcare Software Firm Lyric
Private equity giant TPG is weighing a sale of healthcare software company Lyric at a $5B valuation, per Reuters.
TPG is exploring a sale of Lyric, its healthcare software portfolio company, at a price tag around $5 billion, according to a Reuters report cited by SeekingAlpha. If the deal closes anywhere near that number, it would mark a substantial PE exit in the healthcare tech space — a sector that has seen choppy dealmaking over the past two years.
Lyric operates in healthcare revenue cycle management, a corner of the market that quietly powers how hospitals and insurers settle up. That's a sticky, recurring-revenue business — exactly the kind of asset that commands premium multiples when buyers are competing for durable cash flows.
Read more Brent Crude Tops $100 as Trump Signals No Quick Oil Relief →
For traders, the $5B figure is the number to watch. It signals TPG believes strategic buyers or rival PE shops still have appetite for healthcare SaaS at scale, even as interest rates have pressured leveraged buyout math across the board. A deal here could act as a comp for other healthcare software names in your portfolio.
TPG went public in January 2022 and has been actively managing its portfolio toward realizations. A Lyric sale would bolster distributions to fund investors and potentially free up capital for new bets. Watch TPG's stock for any reaction as deal chatter heats up — these kinds of Reuters-sourced leaks rarely come without a process already in motion.
Continue reading at SeekingAlpha.
